Your fact-checks will appear here
Prescription obesity medications like tirzepatide and semaglutide have produced large, reproducible effects in clinical trials.
Tirzepatide is a dual GIP/GLP‑1 receptor agonist approved for type 2 diabetes and chronic weight management that shows substantial efficacy but carries a predictable cluster of adverse effects—primari...
Dual GIP/GLP‑1 agonists like tirzepatide reduce weight and improve multiple cardiometabolic risk factors that plausibly lower heart‑failure events in obese patients, particularly HFpEF, via hemodynami...
Systematic reviews find that most over‑the‑counter “fat‑burner” supplements produce little or no clinically meaningful weight loss, while a small set of nutraceuticals show modest, peer‑reviewed benef...